Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(01): 093-094
DOI: 10.4103/2278-330X.126577
Letters to the Editor

HPV vaccination in India

Joel Palefsky
Department of Medicine, Division of Infectious Diseases, 513 Parnassus Ave Room S420, Box 0654, University of California, San Francisco
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
31 December 2020

© 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Gupta S, Kerkar RA, Dikshit R, Badwe RA. Is human papillomavirus vaccination likely to be a useful strategy in India? South Asian J Cancer 2013;2:193-7.
  • 2 Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx, [Last accessed on 2013 Dec 13].
  • 3 Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up. Hum Vaccin Immunother 2012;8:390-7.
  • 4 Rowhani-Rahbar A, Alvarez FB, Bryan JT, Hughes JP, Hawes SE, Weiss NS, et al. J Clin Virol. 2012 Mar; 53 (3):239-43.
  • 5 Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011;7:230-8.
  • 6 Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7.
  • 7 Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 United States. MMWR Morb Mortal Wkly Rep 2013;62:591-5.
  • 8 Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. Vaccine 2013;31:3863-71.
  • 9 Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14:244-51.